What it's for (Indications)
- This fixed-dose combination medication, containing metformin and vildagliptin, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).
- It is primarily used when monotherapy with either metformin or a dipeptidyl peptidase-4 (DPP-4) inhibitor (like vildagliptin) does not provide adequate glycemic control.
- Furthermore, it may be considered for patients who are already treated with a combination of vildagliptin and metformin as separate tablets.
- The dual mechanism of action targets different physiological pathways involved in glucose regulation, making it an effective option for managing hyperglycemia in T2DM patients who require more comprehensive glycemic management beyond lifestyle modifications alone.
- This therapeutic approach aims to achieve and maintain individualized HbA1c targets, thereby reducing the risk of diabetes-related complications.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of the metformin and vildagliptin combination must be individualized based on the patient's current treatment regimen, effectiveness, and tolerability, while not exceeding the maximum recommended daily doses of either component. Common fixed-dose strengths typically include vildagliptin 50 mg combined with metformin 500 mg, 850 mg, or 1000 mg. The medication is generally administered orally twice daily, with meals, to mitigate gastrointestinal side effects associated with metformin. Patients not currently on metformin should start with a lower dose of the metformin component, which can be gradually titrated upwards to the therapeutic dose to reduce the likelihood of gastrointestinal adverse events. Renal function must be assessed prior to initiation and periodically thereafter, as dosage adjustments or discontinuation may be necessary in patients with declining renal function (eGFR <60 mL/min/1.73m²). |
Safety & Warnings
Common Side Effects
- Common side effects associated with the metformin and vildagliptin combination primarily stem from the metformin component and include gastrointestinal disturbances such as nausea, vomiting, diarrhea, abdominal pain, and a metallic taste in the mouth.
- These symptoms are often transient and can be minimized by gradual dose titration and taking the medication with food.
- Vildagliptin-related adverse effects are generally mild and may include nasopharyngitis, headache, dizziness, and peripheral edema.
- Hypoglycemia can occur, especially when this combination is co-administered with insulin secretagogues (e.
- g.
- , sulfonylureas) or insulin.
- More serious, albeit rare, adverse events include lactic acidosis (a life-threatening metabolic complication of metformin), acute pancreatitis, hepatic dysfunction, and bullous pemphigoid, a severe blistering skin condition reported with DPP-4 inhibitors.
- Long-term metformin use may also lead to vitamin B12 deficiency.
Serious Warnings
- Black Box Warning: **WARNING: POSTMARKETING CASES OF METFORMIN-ASSOCIATED LACTIC ACIDOSIS HAVE RESULTED IN DEATH, HYPOTHERMIA, HYPOTENSION, AND RESISTANT BRADYCARRHYTHMIAS. THE ONSET OF METFORMIN-ASSOCIATED LACTIC ACIDOSIS IS OFTEN SUBTLE, ACCOMPANIED ONLY BY NON-SPECIFIC SYMPTOMS SUCH AS MALAISE, MYALGIAS, RESPIRATORY DISTRESS, SOMNOLENCE, AND ABDOMINAL PAIN. METFORMIN-ASSOCIATED LACTIC ACIDOSIS IS CHARACTERIZED BY ELEVATED BLOOD LACTATE LEVELS (>5 MMOL/L), ANION GAP ACIDOSIS (WITHOUT EVIDENCE OF KETOACIDURIA OR KETONEURIA), AND AN INCREASED LACTATE/PYRUVATE RATIO; METFORMIN PLASMA LEVELS ARE GENERALLY >5 MCG/ML. RISK FACTORS FOR METFORMIN-ASSOCIATED LACTIC ACIDOSIS INCLUDE RENAL IMPAIRMENT, CONCURRENT USE OF CERTAIN DRUGS (E.G., CARBONIC ANHYDRASE INHIBITORS SUCH AS TOPIRAMATE), AGE 65 YEARS OR OLDER, RADIOLOGIC STUDIES WITH CONTRAST, SURGERY AND OTHER PROCEDURES, HYPOXIC STATES (E.G., ACUTE CONGESTIVE HEART FAILURE), EXCESSIVE ALCOHOL INTAKE, AND HEPATIC IMPAIRMENT. IF LACTIC ACIDOSIS IS SUSPECTED, DISCONTINUE METFORMIN/VILDAGLIPTIN AND INITIATE GENERAL SUPPORTIVE MEASURES IN A HOSPITAL SETTING ALONG WITH PROMPT HEMODIALYSIS. COUNSEL PATIENTS AGAINST EXCESSIVE ALCOHOL INTAKE AND INFORM THEM ABOUT SYMPTOMS OF LACTIC ACIDOSIS.**
- Several important warnings and precautions are critical for safe use of metformin and vildagliptin.
- The risk of metformin-associated lactic acidosis, a rare but severe metabolic complication, is significantly increased in the presence of renal impairment, conditions causing tissue hypoxia (e.
- g.
- , acute congestive heart failure, severe infection, acute myocardial infarction), excessive alcohol intake, hepatic impairment, and in older patients.
- Renal function should be monitored regularly, and the drug should be temporarily discontinued before surgical procedures requiring restricted food/fluid intake or iodinated contrast media.
- Patients should be advised on the symptoms of lactic acidosis.
- DPP-4 inhibitors, including vildagliptin, have been associated with postmarketing reports of acute pancreatitis; patients should be instructed to discontinue the drug and seek medical attention if symptoms like persistent severe abdominal pain develop.
- There have also been rare reports of bullous pemphigoid and hepatic enzyme elevations with vildagliptin.
- Hypoglycemia risk increases when co-administered with sulfonylureas or insulin, necessitating dose adjustment of those agents.
- Metformin can also cause vitamin B12 deficiency with long-term use.
How it Works (Mechanism of Action)
The therapeutic efficacy of this combination product is derived from the synergistic actions of its two components. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production (gluconeogenesis) and reducing intestinal absorption of glucose. It also improves insulin sensitivity by enhancing peripheral glucose uptake and utilization in muscle and adipose tissue, without stimulating insulin secretion, thereby carrying a low intrinsic risk of hypoglycemia when used alone. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, selectively inhibits the enzyme DPP-4, which is responsible for the rapid degradation of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preserving the active forms of these incretins, vildagliptin enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon secretion from pancreatic alpha cells, particularly after meals. This dual mechanism effectively lowers both fasting and post-prandial plasma glucose levels.